|
rs1801516
|
|
|
0.070 |
GeneticVariation |
BEFREE |
ATM rs1801516 polymorphism is not associated with overall cancer risk in total population.
|
30384829 |
2018 |
|
rs1801516
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Single Nucleotide Polymorphism rs1801516 in Ataxia Telangiectasia-Mutated Gene Predicts Late Fibrosis in Cancer Patients After Radiotherapy: A PRISMA-Compliant Systematic Review and Meta-Analysis.
|
27057881 |
2016 |
|
rs1801516
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Our meta-analyses confirmed the presence of a gene-environment interaction between the rs1801516 polymorphism and radiation exposure in carcinogenesis, whereas no association was found between the rs1801516 polymorphism and cancer risk for individuals without radiation exposure.
|
27764772 |
2016 |
|
rs1801516
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Meta-analysis of associations between ATM Asp1853Asn and TP53 Arg72Pro polymorphisms and adverse effects of cancer radiotherapy.
|
25605158 |
2014 |
|
rs1801516
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The IVS24-9 T/(-T), IVS38-8 T/C, 5557 G/A composite genotype alone or in combination with certain genetic background and/or environmental factors, could modify the cancer risk by increasing genetic instability or by altering the effect of the normal DNA damage response.
|
18433505 |
2008 |
|
rs1801516
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Neither of the two common variants, 5557G>A and ivs38-8T>C, nor any haplotype containing them, was significantly associated with breast cancer risk, bilateral breast cancer or multiple primary cancers in any of the patient groups or subgoups.
|
16914028 |
2006 |
|
rs1801516
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Based on the results, we propose a cancer risk-modifying effect for the ATM 5557G-->A, IVS38-8T-->C composite allele.
|
15756685 |
2005 |
|
rs189037
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Summary results indicated that an association was found between rs189037 and cancer risk.
|
30709340 |
2019 |
|
rs189037
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Results indicated a significant association of <i>ATM</i> rs189037 with cancer risk.
|
31201228 |
2019 |
|
rs587776551
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Compared with 51 patients with classic A-T from the Dutch cohort, patients with <i>ATM</i> c.3576G>A had a longer survival and were less likely to develop cancer, respiratory disease or immunodeficiency.
|
30819809 |
2019 |
|
rs664143
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the subgroup analysis by region, we also observed that individuals with ATM rs664143 GA or AA genotype had an obvious increased cancer risk among Asian people (GA vs. GG: OR = 1.40, 95% CI 1.20-1.63, AA vs. GG: OR = 1.37, 95% CI 1.16-1.62).
|
22203481 |
2012 |
|
rs664677
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the subgroup analysis by cancer type, we observed that the ATM rs664143 polymorphism was significantly associated with lung cancer risk (GA vs. GG: OR = 1.48, 95% CI 1.18-1.85, AA vs. GG: OR = 1.51, 95% CI 1.18-1.93) and rs664677 polymorphism was associated with decreased lung cancr risk and increased breast cancer risk (for lung cancer: TC vs. TT: OR = 0.76, 95% CI 0.62-0.92, CC vs. TT: OR = 0.80, 95% CI 0.64-0.99 and for breast cancer: TC vs. TT: OR = 1.42, 95% CI 1.17-1.73, CC vs. TT: OR = 1.51, 95% CI 1.21-1.87).
|
22203481 |
2012 |
|
rs564652222
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Genotype/phenotype relationships were compared: three deleterious missense variants were associated with an increased risk of cancer (c.6679C>T, c.7271T>G, and c.8494C>T).
|
18634022 |
2009 |
|
rs587779872
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Genotype/phenotype relationships were compared: three deleterious missense variants were associated with an increased risk of cancer (c.6679C>T, c.7271T>G, and c.8494C>T).
|
18634022 |
2009 |
|
rs1800054
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Multifactorially adjusted hazard ratios for ATM Ser49Cys heterozygotes versus noncarriers were 1.2 (95% CI, 0.9 to 1.5) for cancer overall, 0.8 (95% CI, 0.3 to 2.0) for breast cancer, 4.8 (95% CI, 2.2 to 11) for melanoma, 2.3 (95% CI, 1.1 to 5.0) for prostate cancer, and 3.4 (95% CI, 1.1 to 11) for cancer of the oral cavity/pharynx.
|
18565893 |
2008 |
|
rs4986761
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Multifactorially adjusted hazard ratios for ATM Ser707Pro heterozygotes versus noncarriers were 0.8 (95% CI, 0.6 to 1.2) for cancer overall, 0.6 (95% CI, 0.2 to 1.6) for breast cancer, 10 (95% CI, 1.1 to 93) for thyroid/other endocrine tumors, and 2.7 (95% CI, 1.0 to 7.6) for cancer of corpus uteri.
|
18565893 |
2008 |
|
rs376676328
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Interestingly, results from functional analysis of the breast cancer-associated ATM mutations indicated that cancer susceptibility is not restricted to mutations with dominant-negative effect on kinase activity, displayed only by 7570G>C, whereas 8734A>G showed only a partial defect in the phosphorylation of ATM substrates, and 6903insA seemed to be a null allele.
|
17166884 |
2007 |
|
rs769142993
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Interestingly, results from functional analysis of the breast cancer-associated ATM mutations indicated that cancer susceptibility is not restricted to mutations with dominant-negative effect on kinase activity, displayed only by 7570G>C, whereas 8734A>G showed only a partial defect in the phosphorylation of ATM substrates, and 6903insA seemed to be a null allele.
|
17166884 |
2007 |
|
rs1800056
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Further SNPs associated with CRC risk included several previously reported to be associated with cancer risk including ATM F858L [OR=1.48; 95% confidence interval (CI): 1.06-2.07] and P1054R (OR=1.42; 95% CI: 1.14-1.77) and MTHFR A222V (OR=0.82; 95% CI: 0.69-0.97).
|
17000706 |
2006 |
|
rs1800057
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Further SNPs associated with CRC risk included several previously reported to be associated with cancer risk including ATM F858L [OR=1.48; 95% confidence interval (CI): 1.06-2.07] and P1054R (OR=1.42; 95% CI: 1.14-1.77) and MTHFR A222V (OR=0.82; 95% CI: 0.69-0.97).
|
17000706 |
2006 |